MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12, 2023.
The conference call will be held on Wednesday, April 12, 2023, hosted by Mr. Paul Lévesque, President and Chief Executive Officer, and begin at 8:30 a.m. ET. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Mr. Philippe Dubuc, Chief Medical Officer Dr. Christian Marsolais, and Global Commercial Officer Mr. John Leasure, who will be available to answer questions from participants following prepared remarks.
Participants are encouraged to join the call at least ten minutes in advance to secure access.
Conference call dial-in and replay information is below:
| CONFERENCE CALL INFORMATION | |
| Conference Call Date: | April 12, 2023 |
| Conference Call Time: | 8:30 AM ET |
| North America Dial-in: | 1-877-513-4119 |
| International Dial-in: | 1-412-902-6615 |
| Access Code: | 4314981 |
| CONFERENCE CALL REPLAY | |
| North America Dial-in: | 1-877-344-7529 |
| International Dial-in: | 1-412-317-0088 |
| Replay Access Code: | 8857934 |
| Replay End Date | April 19, 2023 |
The live conference call will be accessible via webcast at: https://edge.media-server.com/mmc/p/nt9j2fgq
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Investor Inquiries:
Elif McDonald
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-8563
Media Inquiries:
Julie Schneiderman
Senior Director, Communications and Corporate Affaires
This email address is being protected from spambots. You need JavaScript enabled to view it.
1 514 336-7800
| Last Trade: | US$1.18 |
| Daily Change: | -0.04 -3.28 |
| Daily Volume: | 62,935 |
| Market Cap: | US$54.260M |
October 10, 2024 October 09, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
